Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca (NYSE:AZN) announced that an FDA Oncologic Drugs Advisory Committee (ODAC) voted 7-1 with 1 abstention that TRUQAP (capivasertib) plus abiraterone and ADT has a favorable benefit-risk profile for PTEN-deficient metastatic hormone-sensitive prostate cancer based on CAPItello-281.
CAPItello-281 showed a 19% reduction in risk of radiographic progression or death (HR 0.81; 95% CI 0.66-0.98; P=0.034), with median rPFS 33.2 vs 25.7 months (improvement 7.5 months). Grade ≥3 adverse events occurred in 67% vs 40.4% (comparator); OS data remain immature.
Pinetree Therapeutics announced AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option to obtain an exclusive global license to develop and commercialize PTX-299, a bispecific antibody degrader targeting EGFR.
The option exercise triggers a $25 million option-closing payment to Pinetree and makes AstraZeneca responsible for global development and commercialization; the deal includes future development, regulatory, and commercial milestones plus tiered royalties, with total potential value exceeding $500 million.
AstraZeneca (NYSE:AZN) reported Q1 2026 Total Revenue of $15,288m (CER +8%) and Product Revenue of $15,211m. Core EPS was $2.58 and reported EPS $1.99. Growth was driven by double‑digit Oncology and Rare Disease performance and multiple Phase III positive readouts and approvals.
Guidance for FY 2026 at CER was reconfirmed: mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS growth; Core tax rate 18–22%.
AstraZeneca (NYSE: AZN) announced FDA approval of BREZTRI Aerosphere for maintenance treatment of asthma in patients 12 years and older, marking the first single-inhaler fixed-dose triple therapy approved for this population.
Approval was based on Phase III KALOS and LOGOS (≈4,300 patients) showing significant FEV1 improvement versus ICS/LABA and a rapid onset of action within five minutes; no new safety signals identified. BREZTRI was prescribed to >6.8 million patients globally in 2025.
AstraZeneca (NYSE: AZN) announced FDA approval (April 27, 2026) of SAPHNELO Pen for once-weekly subcutaneous self-administration of anifrolumab for adults with moderate-to-severe systemic lupus erythematosus (SLE) on standard therapy. Approval follows Phase III TULIP-SC, which met its primary endpoint (BICLA at Week 52) and reported safety consistent with IV use.
The autoinjector expands access beyond IV infusion, complements existing approvals in the EU and Japan, and follows an updated agreement to pay Bristol-Myers Squibb a mid-teens US royalty.
AstraZeneca (NYSE:AZN) reported that tozorakimab met the primary endpoint in the Phase III MIRANDA trial, showing a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in former smokers and the overall population. MIRANDA randomized 1,454 patients and tested tozorakimab 300mg every two weeks versus placebo on top of inhaled standard of care over 52 weeks. Tozorakimab was generally well tolerated with a safety profile consistent with prior trials. Data will be submitted to regulators and presented at a medical meeting.
AstraZeneca (AZN) reported positive interim EMERALD-3 Phase III results on April 2, 2026: IMFINZI (durvalumab) + IMJUDO (tremelimumab-actl) combined with lenvatinib and TACE produced a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for embolization-eligible unresectable hepatocellular carcinoma.
The combination also showed a trend toward improved overall survival (OS); safety profiles were consistent with known profiles and no new safety findings were reported. Data will be presented at a medical meeting and shared with regulators.
AstraZeneca (NYSE:AZN) reported that tozorakimab met the primary endpoint in both Phase III OBERON and TITANIA trials, reducing the annualized rate of moderate-to-severe COPD exacerbations versus placebo in former smokers and the overall population. Trials randomized 2,306 patients; dosing was 300 mg every four weeks. Tozorakimab was generally well tolerated. Additional Phase III trials PROSPERO (1,713 randomized) and MIRANDA (1,454) are ongoing with results expected in H1 2026.
AstraZeneca (NYSE: AZN) on March 10, 2026 launched the national Get Body Checked Against Cancer public health campaign featuring actor Joshua Jackson and the Philadelphia Flyers mascot Gritty.
The campaign promotes conversations with doctors about cancer risk and screenings, supports Hockey Fights Cancer, and notes a $1.1 million donation to the V Foundation. Visit Getbodychecked.com for resources and screening locations.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced the FDA has accepted the sBLA for ENHERTU as post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer and granted Priority Review. The Prescription Drug User Fee Act action date is anticipated in Q3 2026 and the application is under Project Orbis.
Approval is supported by DESTINY‑Breast05 Phase III data showing a 53% reduction in risk of invasive disease recurrence or death (HR 0.47; 95% CI 0.34–0.66) and three‑year IDFS 92.4% vs 83.7% with T‑DM1. Safety highlights include ILD risk and established warnings.